WEB DESK: Researchers are leveraging robotic technology to enhance the detection and elimination of treatment-resistant cancer cells, known as “persister” cells, which are often responsible for cancer recurrence. These elusive cells are extremely rare sometimes just one in a thousand tumor cells and challenging to identify, but they play a critical role in the return of the disease.
Focusing on lung cancer samples, scientists uncovered nearly 10,000 genetic variations that could enable cancer cells to evade therapy. To evaluate potential treatments efficiently, instead of conducting 10,000 lengthy experiments, they developed an automated robotic platform featuring hundreds of miniature tumor models housed in controlled incubators. The robotic arm moved the samples through various testing stations.
Out of 94 drugs tested, nine demonstrated consistent effectiveness against these resilient cells, suggesting that such cells may share common vulnerabilities regardless of the treatment received. Senior researcher Steve Altschuler from UC San Francisco explained, “We anticipated each tumor to behave uniquely, but instead, we identified patterns that could help predict which therapies are most promising.”
Innovative Blood Vessel Blockade Offers Long-Lasting Knee Osteoarthritis Relief
A novel minimally invasive procedure that blocks abnormal blood vessels around the knee shows promising results for relieving severe osteoarthritis pain without the need for surgery. Conducted in Germany, genicular artery embolization (GAE) involves guiding a thin catheter directly into affected vessels and injecting tiny particles to block abnormal blood flow, reducing inflammation and pain.
Dr. Florian Nima Fleckenstein of Charité – Universitätsmedizin Berlin stated, “Many patients with knee osteoarthritis face limited options today. Traditional injections often don’t provide sufficient relief, and surgery isn’t always suitable.”
In a study involving 194 patients who had not responded to at least three months of conventional treatments, pain levels significantly decreased—from an average score of 7 to 4 at six weeks, and further down to 3 at six and 12 months follow-up. Additionally, patients reported notable improvements in other symptoms and overall quality of life over the course of a year.
Fleckenstein emphasized the real-world applicability of these findings, noting, “These results are meaningful because they reflect what we see in everyday clinical practice, offering hope for many patients seeking alternatives to surgery.”
